Literature DB >> 24738700

Norfolk QOL-DN: validation of a patient reported outcome measure in transthyretin familial amyloid polyneuropathy.

Etta J Vinik1, Aaron I Vinik, James F Paulson, Ingemar S J Merkies, Jeff Packman, Donna R Grogan, Teresa Coelho.   

Abstract

The Norfolk Quality of Life-Diabetic Neuropathy (QOL-DN) questionnaire is an instrument to assess QOL in diabetic polyneuropathy. The objective of this observational, cross-sectional study in 61 patients with V30M transthyretin familial amyloid polyneuropathy (TTR-FAP) and 16 healthy volunteers was to validate the Norfolk QOL-DN for assessment of QOL in TTR-FAP. Comparisons were conducted to identify the best items to discriminate disease stages and assess which individual Norfolk domains (symptoms, large fiber, small fiber, autonomic, and activities of daily living) would be most affected by disease stage. Analysis of individual items revealed a significant pattern of discrimination among disease stages (p < 0.001). Total QOL scores increased (indicating worsening) with duration of symptoms, with a steeper increase observed earlier in the course of disease. Significant correlations were observed between each Norfolk domain and other measures of neurological function. Limitations include cross-sectional study design, low patient numbers in this rare disease, and the ordinal-based character of the metric used; future areas to explore include item response theory approaches such as Rasch analysis. These results suggest the Norfolk QOL-DN is a reliable indicator of the impact of disease severity on QOL in patients with TTR-FAP.
© 2014 Peripheral Nerve Society.

Entities:  

Keywords:  Norfolk quality of life; nerve-fiber function; neurological function; outcome measure; transthyretin amyloid polyneuropathy

Mesh:

Substances:

Year:  2014        PMID: 24738700     DOI: 10.1111/jns5.12059

Source DB:  PubMed          Journal:  J Peripher Nerv Syst        ISSN: 1085-9489            Impact factor:   3.494


  25 in total

Review 1.  Autonomic involvement in hereditary transthyretin amyloidosis (hATTR amyloidosis).

Authors:  Alejandra Gonzalez-Duarte
Journal:  Clin Auton Res       Date:  2018-03-06       Impact factor: 4.435

Review 2.  Content validity of symptom-based measures for diabetic, chemotherapy, and HIV peripheral neuropathy.

Authors:  Jennifer S Gewandter; Laurie Burke; Guido Cavaletti; Robert H Dworkin; Christopher Gibbons; Tony D Gover; David N Herrmann; Justin C Mcarthur; Michael P McDermott; Bob A Rappaport; Bryce B Reeve; James W Russell; A Gordon Smith; Shannon M Smith; Dennis C Turk; Aaron I Vinik; Roy Freeman
Journal:  Muscle Nerve       Date:  2016-12-23       Impact factor: 3.217

Review 3.  The New Age of Sudomotor Function Testing: A Sensitive and Specific Biomarker for Diagnosis, Estimation of Severity, Monitoring Progression, and Regression in Response to Intervention.

Authors:  Aaron I Vinik; Marie-Laure Nevoret; Carolina Casellini
Journal:  Front Endocrinol (Lausanne)       Date:  2015-06-11       Impact factor: 5.555

4.  Post hoc analysis of nutritional status in patients with transthyretin familial amyloid polyneuropathy: impact of tafamidis.

Authors:  Ole B Suhr; Isabel M Conceição; Onur N Karayal; Francine S Mandel; Pedro E Huertas; Bo-Göran Ericzon
Journal:  Neurol Ther       Date:  2014-12-11

5.  Cardiac findings and events observed in an open-label clinical trial of tafamidis in patients with non-Val30Met and non-Val122Ile hereditary transthyretin amyloidosis.

Authors:  Thibaud Damy; Daniel P Judge; Arnt V Kristen; Karine Berthet; Huihua Li; Janske Aarts
Journal:  J Cardiovasc Transl Res       Date:  2015-03-06       Impact factor: 4.132

6.  Management of asymptomatic gene carriers of transthyretin familial amyloid polyneuropathy.

Authors:  Hartmut H-J Schmidt; Fabio Barroso; Alejandra González-Duarte; Isabel Conceição; Laura Obici; Denis Keohane; Leslie Amass
Journal:  Muscle Nerve       Date:  2016-09       Impact factor: 3.217

7.  Delay between Onset of Symptoms and Seeking Physician Intervention Increases Risk of Diabetic Foot Complications: Results of a Cross-Sectional Population-Based Survey.

Authors:  Norina A Gavan; Ioan A Veresiu; Etta J Vinik; Aaron I Vinik; Bogdan Florea; Cosmina I Bondor
Journal:  J Diabetes Res       Date:  2016-11-29       Impact factor: 4.011

Review 8.  Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy.

Authors:  David Adams; Yukio Ando; João Melo Beirão; Teresa Coelho; Morie A Gertz; Julian D Gillmore; Philip N Hawkins; Isabelle Lousada; Ole B Suhr; Giampaolo Merlini
Journal:  J Neurol       Date:  2020-01-06       Impact factor: 4.849

9.  Trial design and rationale for APOLLO, a Phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy.

Authors:  David Adams; Ole B Suhr; Peter J Dyck; William J Litchy; Raina G Leahy; Jihong Chen; Jared Gollob; Teresa Coelho
Journal:  BMC Neurol       Date:  2017-09-11       Impact factor: 2.474

10.  Positive Effectiveness of Tafamidis in Delaying Disease Progression in Transthyretin Familial Amyloid Polyneuropathy up to 2 Years: An Analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS).

Authors:  Rajiv Mundayat; Michelle Stewart; Jose Alvir; Sarah Short; Moh-Lim Ong; Denis Keohane; Denise Rill; Marla B Sultan
Journal:  Neurol Ther       Date:  2018-04-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.